AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24799482 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-negative residues after chemotherapy (548 patients)
Number of subjects: 739
Study 24799482 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive patients receiving additional radiotherapy (191 patients)
Number of subjects: 739
Study 24799482 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive patients with relative reduction of less than 40% (54 patients)
Number of subjects: 739
Study 24799482 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-positive patients with larger reduction
Number of subjects: 739
Study 22443921 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression with hemostatic patch
Number of subjects: 89
Study 22443921 — intervention group
Group type: COMPARATOR
Intervention: Manual compression alone (control group)
Number of subjects: 89
Study 22443921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (manual compression with and without hemostatic patch)
Number of subjects: 89
Study 20185734 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin (OI) - 300 units combined with 400 mg of delivery agent orally
Number of subjects: 10
Study 20185734 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous regular human insulin (RHI) - 15 units
Number of subjects: 10
Study 18602250 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplements containing 60 mg of iron and 250 microg of folic acid plus 25 mg of zinc
Number of subjects: 242
Study 18602250 — intervention group
Group type: COMPARATOR
Intervention: Daily supplements containing 60 mg of iron and 250 microg of folic acid
Number of subjects: 242
Study 11465711 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (specific treatments not detailed)
Number of subjects: 182
Study 11465711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 10036659 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometrically diploid tumours
Number of subjects: 116
Study 10036659 — intervention group
Group type: COMPARATOR
Intervention: Aneuploid tumours
Number of subjects: 116
Study 10036659 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneuploid T1 tumours
Number of subjects: 116
Study 10036659 — intervention group
Group type: EXPERIMENTAL
Intervention: Diploid T1 tumours
Number of subjects: 116
Study 8158065 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous patch (Group B)
Number of subjects: 188
Study 8158065 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic Gore-Tex patch (Group C)
Number of subjects: 188
Study 8158065 — intervention group
Group type: COMPARATOR
Intervention: Direct closure (Group A)
Number of subjects: 188
Study 2895124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexetidine containing toothpaste
Number of subjects: 0
Study 2895124 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 0
Study 2895124 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme containing toothpaste
Number of subjects: 0
Study 2895124 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride toothpaste
Number of subjects: 0
Study 2895124 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual antibacterial activity with hexetidine toothpaste
Number of subjects: 0
Study 2895124 — intervention group
Group type: COMPARATOR
Intervention: Residual antibacterial activity with chlorhexidine gel
Number of subjects: 0
Study 30179280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-PEPSONE programme (CPP)
Number of subjects: 35
Study 30179280 — intervention group
Group type: COMPARATOR
Intervention: Support as usual (Control)
Number of subjects: 35
Study 28082387 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) at 90% to 95% of maximal heart rate
Number of subjects: 261
Study 28082387 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT) at 60% to 70% of maximal heart rate
Number of subjects: 261
Study 28082387 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 261
Study 28082387 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 261
Study 28082387 — intervention group
Group type: COMPARATOR
Intervention: Regular Exercise Recommendation (RRE)
Number of subjects: 261
Study 26073754 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM extract (active) administered orally twice daily for 12 months
Number of subjects: 111
Study 26073754 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution administered orally twice daily for 12 months
Number of subjects: 111
Study 24016147 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA)
Number of subjects: 64
Study 24016147 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (CA)
Number of subjects: 64
Study 24016147 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA) in patients with paroxysmal AF (PAF)
Number of subjects: 64
Study 24016147 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (CA) in patients with paroxysmal AF (PAF)
Number of subjects: 64
Study 24016147 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ablation (SA) in patients with persistent AF (PersAF)
Number of subjects: 64
Study 24016147 — intervention group
Group type: COMPARATOR
Intervention: Catheter ablation (CA) in patients with persistent AF (PersAF)
Number of subjects: 64
Study 21421174 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-based preventive intervention implemented 3 months before the traumatic exposure.
Number of subjects: 1488
Study 21421174 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group exposed to the same traumatic events.
Number of subjects: 1488
Study 19590194 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 37.5 mg twice daily for 14 days (pilot study)
Number of subjects: 23
Study 19590194 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 25 mg once daily for 28 days (phase II study)
Number of subjects: 23
Study 19590194 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 50 mg once daily for 28 days (phase II study)
Number of subjects: 23
Study 19590194 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 75 mg once daily for 28 days (phase II study)
Number of subjects: 23
Study 19590194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16520399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 20
Study 16520399 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 20
Study 15253827 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 mL of cold anesthetic gel (group 1)
Number of subjects: 33
Study 15253827 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain lubricating gel (group 2)
Number of subjects: 33
Study 15253827 — intervention group
Group type: COMPARATOR
Intervention: No gel (group 3)
Number of subjects: 33
Study 10689265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI)
Number of subjects: 20
Study 9243105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting immunoreactive insulin
Number of subjects: 170
Study 9243105 — intervention group
Group type: EXPERIMENTAL
Intervention: Total immunoreactive proinsulin
Number of subjects: 170
Study 9243105 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinsulin/specific insulin ratio
Number of subjects: 170
Study 9243105 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific insulin
Number of subjects: 170
Study 9243105 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinsulin and proinsulin/specific insulin ratio
Number of subjects: 170
Study 9243105 — intervention group
Group type: EXPERIMENTAL
Intervention: High proinsulin/specific insulin ratio
Number of subjects: 170
Study 8440766 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine per day
Number of subjects: 24
Study 8440766 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg nicotine per day
Number of subjects: 24
Study 8440766 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine per day
Number of subjects: 24
Study 8440766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Transdermal System 21 mg/day
Number of subjects: 24
Study 8440766 — intervention group
Group type: COMPARATOR
Intervention: Combined administration of Nicotine Transdermal System 7 mg/day plus 14 mg/day
Number of subjects: 24
Study 29584456 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab alone
Number of subjects: 0
Study 29584456 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab in combination with pegylated liposomal doxorubicin
Number of subjects: 0
Study 29584456 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin alone
Number of subjects: 0
Study 28857740 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind drug reduction programme leading to full withdrawal within 6 months.
Number of subjects: 22
Study 28857740 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group maintained baseline level of medication).
Number of subjects: 22
Study 26616122 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure intervention plus usual care
Number of subjects: 298
Study 26616122 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 298
Study 23017512 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete bladder neck preservation
Number of subjects: 208
Study 23017512 — intervention group
Group type: COMPARATOR
Intervention: No preservation (control)
Number of subjects: 208
Study 21352671 — intervention group
Group type: EXPERIMENTAL
Intervention: New chest physiotherapy method (CPT) with 31 sessions of nebulization of hypertonic saline followed by CPT
Number of subjects: 20
Study 21352671 — intervention group
Group type: COMPARATOR
Intervention: Nebulization of hypertonic saline (27 sessions)
Number of subjects: 20
Study 19011554 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte transplantation on a 3-dimensional matrix
Number of subjects: 0
Study 19011554 — intervention group
Group type: COMPARATOR
Intervention: Traditional ACI methods
Number of subjects: 0
Study 16157462 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers in precontemplation stage
Number of subjects: 633
Study 16157462 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparers
Number of subjects: 633
Study 16157462 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients preparing to quit
Number of subjects: 633
Study 16157462 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers contemplating quitting and preparing to quit
Number of subjects: 633
Study 16157462 — intervention group
Group type: COMPARATOR
Intervention: Unmotivated smokers
Number of subjects: 633
Study 16157462 — intervention group
Group type: COMPARATOR
Intervention: Smokers motivated to quit
Number of subjects: 633
Study 14632625 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable pain (100% probability)
Number of subjects: 16
Study 14632625 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable pain (50% probability)
Number of subjects: 16
Study 14632625 — intervention group
Group type: COMPARATOR
Intervention: Comparison between predictable and unpredictable conditions
Number of subjects: 16
Study 11071974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - Oral conjugated oestrogen (0.625 mg) + medroxyprogesterone acetate (2.5 mg) daily for 12 weeks
Number of subjects: 65
Study 11071974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study 9068933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/day
Number of subjects: 25
Study 9068933 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study 8450327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous nicardipine
Number of subjects: 906
Study 8450327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 906
Study 3785647 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg
Number of subjects: 0
Study 29720244 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurolidine-citrate lock solution
Number of subjects: 0
Study 29720244 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone (placebo)
Number of subjects: 0
Study 26463420 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 40
Study 26463420 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Therapy (MAD)
Number of subjects: 40
Study 25257877 — intervention group
Group type: EXPERIMENTAL
Intervention: OCC (occlusion)
Number of subjects: 7
Study 25257877 — intervention group
Group type: EXPERIMENTAL
Intervention: RI (ramp incremental exercise)
Number of subjects: 7
Study 25257877 — intervention group
Group type: EXPERIMENTAL
Intervention: SVR (severe-intensity exercise)
Number of subjects: 7
Study 25257877 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (moderate-intensity exercise)
Number of subjects: 7
Study 25257877 — intervention group
Group type: EXPERIMENTAL
Intervention: VLP (vastus lateralis proximal)
Number of subjects: 7
Study 23158856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 100 mg intravenous, 3 times/day for 7 days
Number of subjects: 26
Study 23158856 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 26
Study 20627914 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilators (salbutamol plus ipratropium)
Number of subjects: 12
Study 20627914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19097963 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 132
Study 19097963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg/kg
Number of subjects: 132
Study 19097963 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.4 mg/kg
Number of subjects: 132
Study 19097963 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 132
Study 16177972 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinilin (Echinacea purpurea) administered at onset of cold for 7 days, 5 mL/dose on day 1 and 3 doses on subsequent days
Number of subjects: 0
Study 16177972 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at onset of cold for 7 days
Number of subjects: 0
Study 12952843 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) for 3 days (GTN+ARB group)
Number of subjects: 64
Study 12952843 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (10 mg/d) for 3 days (GTN group)
Number of subjects: 64
Study 12952843 — intervention group
Group type: COMPARATOR
Intervention: Placebo skin patches and placebo tablets for 3 days (control group)
Number of subjects: 64
Study 12952843 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nitroglycerin (10 mg/d) (GTN group)
Number of subjects: 64
Study 12952843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 64
Study 12952843 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg/d) and ARB (candesartan, 8 mg/d) (GTN+ARB group)
Number of subjects: 64
Study 9892314 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day of glycine (N=9)
Number of subjects: 19
Study 9892314 — intervention group
Group type: COMPARATOR
Intervention: Clozapine without glycine (N=10)
Number of subjects: 19
Study 10829989 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with severe malnutrition (grades III and IV PEM)
Number of subjects: 58
Study 10829989 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with marked linear growth retardation (height-for-age < 85% of normal)
Number of subjects: 58
Study 10829989 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished children with hypoalbuminemia (serum albumin < 2.5 g/dl)
Number of subjects: 58
Study 10829989 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished children with anemia (hemoglobin < or = 8.0 g/dl)
Number of subjects: 58
Study 10829989 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 children without PEM)
Number of subjects: 58
Study 1866346 — intervention group
Group type: EXPERIMENTAL
Intervention: Denis‐Browne splint
Number of subjects: 0
Study 6625248 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg . kg‐1 and fentanyl 6 micrograms . kg‐1 (Group M)
Number of subjects: 19
Study 6625248 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 6 mg . kg‐1 and fentanyl 5 micrograms . kg‐1 (Group T)
Number of subjects: 19
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Disease Activity (VLDA)
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Activity Index for PsA (DAPSA)
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical (c-) DAPSA
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA 5/7
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA skin
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA joint
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA joint + skin
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPSA LDA
Number of subjects: 0
Study 30323006 — intervention group
Group type: EXPERIMENTAL
Intervention: cDAPSA LDA
Number of subjects: 0
Study 29041916 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated rehabilitation programme with early onset of patient participation and intensified occupational therapy and physiotherapy after hip fracture surgery.
Number of subjects: 126
Study 29041916 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group).
Number of subjects: 126
Study 26666500 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50 mg/day
Number of subjects: 106
Study 26666500 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 150 mg/day
Number of subjects: 106
Study 26666500 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 5 mg/day
Number of subjects: 106
Study 26666500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N01187)
Number of subjects: 106
Study 26666500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N01236)
Number of subjects: 106
Study 24183608 — intervention group
Group type: EXPERIMENTAL
Intervention: €5 cash incentive
Number of subjects: 1650
Study 24183608 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry into a prize draw
Number of subjects: 1650
Study 24183608 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 1650
Study 23766611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Steroids
Number of subjects: 30
Study 23766611 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Steroids
Number of subjects: 30
Study 20446083 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN/ODV AUC metabolic ratio
Number of subjects: 141
Study 20446083 — intervention group
Group type: EXPERIMENTAL
Intervention: ODV/VEN AUC metabolic ratio
Number of subjects: 141
Study 17220728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.05 mmol/kg)
Number of subjects: 60
Study 15751604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with APS1
Number of subjects: 11
Study 15751604 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 sex‐ and age‐matched healthy subjects)
Number of subjects: 11
Study 12081605 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin-alpha1 and famciclovir combination therapy
Number of subjects: 32
Study 12081605 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir monotherapy
Number of subjects: 32
Study 12081605 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study 10365354 — intervention group
Group type: EXPERIMENTAL
Intervention: GORD infants
Number of subjects: 20
Study 10365354 — intervention group
Group type: EXPERIMENTAL
Intervention: GORD infants (videofluoroscopy)
Number of subjects: 20
Study 7491382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 21
Study 7491382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2024560 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (0.03 mg.kg‐1 to 0.25 mg.kg‐1) with fentanyl
Number of subjects: 30
Study 2024560 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane and fentanyl
Number of subjects: 30
Study 7042799 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized ragweed (PRW)
Number of subjects: 21
Study 7042799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7042799 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 21
Study 30764731 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-based machine learning (ML) algorithm
Number of subjects: 1501
Study 27046461 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% + tramadol 1 mg/kg
Number of subjects: 65
Study 27046461 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25% + tramadol 2 mg/kg
Number of subjects: 65
Study 27046461 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 0.25% (Control)
Number of subjects: 65
Study 26435060 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose consumption (25% of daily energy requirements)
Number of subjects: 113
Study 26435060 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose consumption (25% of daily energy requirements)
Number of subjects: 113
Study 26435060 — intervention group
Group type: COMPARATOR
Intervention: High fructose corn syrup (HFCS) consumption (25% of daily energy requirements)
Number of subjects: 113
Study 23400741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg
Number of subjects: 12
Study 23400741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn)
Number of subjects: 12
Study 21175273 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 13
Study 21175273 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 13